BIO-GATE AG (BIG1.DE) Fundamental Analysis & Valuation

FRA:BIG1 • DE000BGAG981

Current stock price

0.555 EUR
0 (0%)
Last:

This BIG1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BIG1.DE Profitability Analysis

1.1 Basic Checks

  • BIG1 had negative earnings in the past year.
  • In the past year BIG1 has reported a negative cash flow from operations.
  • In the past 5 years BIG1 always reported negative net income.
  • In the past 5 years BIG1 always reported negative operating cash flow.
BIG1.DE Yearly Net Income VS EBIT VS OCF VS FCFBIG1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500K -1M -1.5M -2M -2.5M

1.2 Ratios

  • BIG1 has a worse Return On Assets (-32.97%) than 92.86% of its industry peers.
  • BIG1's Return On Equity of -151.10% is on the low side compared to the rest of the industry. BIG1 is outperformed by 91.43% of its industry peers.
Industry RankSector Rank
ROA -32.97%
ROE -151.1%
ROIC N/A
ROA(3y)-33.66%
ROA(5y)-27.14%
ROE(3y)-61.46%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
BIG1.DE Yearly ROA, ROE, ROICBIG1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • BIG1 has a Gross Margin of 57.72%. This is amongst the best in the industry. BIG1 outperforms 87.14% of its industry peers.
  • BIG1's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for BIG1 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.52%
GM growth 5Y-2.6%
BIG1.DE Yearly Profit, Operating, Gross MarginsBIG1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BIG1.DE Health Analysis

2.1 Basic Checks

  • BIG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BIG1 has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BIG1 has more shares outstanding
  • BIG1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BIG1.DE Yearly Shares OutstandingBIG1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
BIG1.DE Yearly Total Debt VS Total AssetsBIG1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • BIG1 has an Altman-Z score of -2.94. This is a bad value and indicates that BIG1 is not financially healthy and even has some risk of bankruptcy.
  • BIG1 has a Altman-Z score of -2.94. This is amonst the worse of the industry: BIG1 underperforms 85.71% of its industry peers.
  • BIG1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.94
ROIC/WACCN/A
WACC7.45%
BIG1.DE Yearly LT Debt VS Equity VS FCFBIG1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • BIG1 has a Current Ratio of 1.85. This is a normal value and indicates that BIG1 is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.85, BIG1 is in line with its industry, outperforming 52.86% of the companies in the same industry.
  • A Quick Ratio of 0.55 indicates that BIG1 may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.55, BIG1 is doing worse than 88.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 0.55
BIG1.DE Yearly Current Assets VS Current LiabilitesBIG1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIG1.DE Growth Analysis

3.1 Past

  • BIG1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.80%, which is quite impressive.
  • BIG1 shows a decrease in Revenue. In the last year, the revenue decreased by -7.53%.
  • Measured over the past years, BIG1 shows a quite strong growth in Revenue. The Revenue has been growing by 15.13% on average per year.
EPS 1Y (TTM)31.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.52%
Revenue 1Y (TTM)-7.53%
Revenue growth 3Y4.19%
Revenue growth 5Y15.13%
Sales Q2Q%-2.1%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.35% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, BIG1 will show a small growth in Revenue. The Revenue will grow by 7.30% on average per year.
EPS Next Y30.3%
EPS Next 2Y31.43%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue Next Year0.33%
Revenue Next 2Y4.18%
Revenue Next 3Y7.3%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BIG1.DE Yearly Revenue VS EstimatesBIG1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M
BIG1.DE Yearly EPS VS EstimatesBIG1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

1

4. BIG1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BIG1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIG1. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIG1.DE Price Earnings VS Forward Price EarningsBIG1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIG1.DE Per share dataBIG1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

  • BIG1's earnings are expected to grow with 25.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.43%
EPS Next 3Y25.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIG1.DE Dividend Analysis

5.1 Amount

  • No dividends for BIG1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIG1.DE Fundamentals: All Metrics, Ratios and Statistics

BIO-GATE AG

FRA:BIG1 (3/17/2026, 7:00:00 PM)

0.555

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)03-02
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.8%
Ins Owner ChangeN/A
Market Cap5.13M
Revenue(TTM)6.98M
Net Income(TTM)-1.38M
Analysts82.5
Price Target3.06 (451.35%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.73
P/FCF N/A
P/OCF N/A
P/B 5.62
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.76
BVpS0.1
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.97%
ROE -151.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.72%
FCFM N/A
ROA(3y)-33.66%
ROA(5y)-27.14%
ROE(3y)-61.46%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.52%
GM growth 5Y-2.6%
F-Score4
Asset Turnover1.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.72%
Cap/Sales 1.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 0.55
Altman-Z -2.94
F-Score4
WACC7.45%
ROIC/WACCN/A
Cap/Depr(3y)91.79%
Cap/Depr(5y)118.01%
Cap/Sales(3y)3.64%
Cap/Sales(5y)4.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.52%
EPS Next Y30.3%
EPS Next 2Y31.43%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-7.53%
Revenue growth 3Y4.19%
Revenue growth 5Y15.13%
Sales Q2Q%-2.1%
Revenue Next Year0.33%
Revenue Next 2Y4.18%
Revenue Next 3Y7.3%
Revenue Next 5YN/A
EBIT growth 1Y30.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.36%
EBIT Next 3Y30.3%
EBIT Next 5YN/A
FCF growth 1Y65.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.93%
OCF growth 3YN/A
OCF growth 5YN/A

BIO-GATE AG / BIG1.DE Fundamental Analysis FAQ

What is the fundamental rating for BIG1 stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIG1.DE.


What is the valuation status for BIG1 stock?

ChartMill assigns a valuation rating of 1 / 10 to BIO-GATE AG (BIG1.DE). This can be considered as Overvalued.


How profitable is BIO-GATE AG (BIG1.DE) stock?

BIO-GATE AG (BIG1.DE) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BIO-GATE AG?

The Earnings per Share (EPS) of BIO-GATE AG (BIG1.DE) is expected to grow by 30.3% in the next year.